Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients

Nov 13, 2008

The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology.

The combination of bevacizumab and chemotherapy has been shown to increase the survival of patients with incurable non-small cell lung cancer. cetuximab has recently demonstrated improved survival when given in combination with platinum based chemotherapy. Based on this information, researchers from M.D. Anderson Cancer Center in Houston, Fred Hutchison Cancer Research Center and the Cancer Research and Biostatistical Clinical Trials Consortium (CRAB), both in Seattle, the Cancer Center of Kansas in Wichita, Kan., Central Illinois CCOP in Springfield, Ill., the University of Kansas in Kansas City, Kan., and U.C. Davis Cancer Center in Sacramento, all part of the South West Oncology Group, sought to investigate the safety and efficacy of the combination of the four drugs in this multi-center phase II clinical trial.

This study, the first reported study of these two targeted therapies (bevacizumab and cetuximab) with chemotherapy (carboplatin and paclitaxel), combined the four drugs as first-line therapy in advanced lung cancer patients. The goal of this study was to assess the safety of the four drug regimen. No safety concerns were seen when compared with other treatments. Additionally, in the 104 patients evaluated between August 2006 and September 2007, improved survival was observed.

"The combination of multiple targeted therapies in addition to chemotherapy may be the future of treatment in lung cancer," said Edward Kim, M.D., lead author of the study and an assistant professor in the department of thoracic/head and neck medical oncology at M.D. Anderson Cancer Center. "Blocking more key cancer pathways such as the epidermal growth factor receptor and vascular endothelial growth factor may lead to improved cancer control."

Source: American Society for Therapeutic Radiology and Oncology

Explore further: Pain and itch may be signs of skin cancer

add to favorites email to friend print save as pdf

Related Stories

Team uses nanoparticles to enhance chemotherapy

Jul 07, 2014

(Phys.org) —University of Georgia researchers have developed a new formulation of cisplatin, a common chemotherapy drug, that significantly increases the drug's ability to target and destroy cancerous cells.

Advancing medicine, layer by layer

Jul 02, 2014

Personalized cancer treatments and better bone implants could grow from techniques demonstrated by graduate students Stephen W. Morton and Nisarg J. Shah, who are both working in chemical engineering professor ...

Fine tuning an old-school chemotherapy drug

May 05, 2014

First approved by the FDA in the 1970s, the chemotherapy drug cisplatin and its relative carboplatin remain mainstays of treatment for lung, head and neck, testicular and ovarian cancer. However, cisplatin's ...

Recommended for you

All-clear for nonlinear optical imaging

55 minutes ago

High power femto-second laser pulses used for in vivo nonlinear optical imaging can form DNA products, which may lead to carcinogenesis. A modified cancer risk model now shows that the cancer risk is negligible ...

Pain and itch may be signs of skin cancer

17 hours ago

Asking patients if a suspicious skin lesion is painful or itchy may help doctors decide whether the spot is likely to be cancerous, according to a new study headed by Gil Yosipovitch, MD, Chairman of the Department of Dermatology ...

Genetics of cancer: Non-coding DNA can finally be decoded

20 hours ago

Cancer is a disease of the genome resulting from a combination of genetic modifications (or mutations). We inherit from our parents strong or weak predispositions to developing certain kinds of cancer; in addition, we also ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

E_L_Earnhardt
1 / 5 (1) Nov 13, 2008
More likely the endothermic reaction, or the sheer quantity of fluid, lowered the reactive TEMPERATURE within the cells and saved the patient! COOLING SLOWS MITOSIS!